Literature DB >> 18830232

Mutational analysis of the ACVR1 gene in Italian patients affected with fibrodysplasia ossificans progressiva: confirmations and advancements.

Renata Bocciardi1, Domenico Bordo, Marco Di Duca, Maja Di Rocco, Roberto Ravazzolo.   

Abstract

Fibrodysplasia ossificans progressiva (FOP, MIM 135100) is a rare genetic disorder characterized by congenital great toe malformations and progressive heterotopic ossification transforming skeletal muscles and connective tissues to bone following a well-defined anatomic pattern of progression. Recently, FOP has been associated with a specific mutation of ACVR1, the gene coding for a bone morphogenetic protein type I receptor. The identification of ACVR1 as the causative gene for FOP now allows the genetic screening of FOP patients to identify the frequency of the identified recurrent ACVR1 mutation and to investigate genetic variability that may be associated with this severely debilitating disease. We report the screening for mutations in the ACVR1 gene carried out in a cohort of 17 Italian patients. Fifteen of these displayed the previously described c.617G>A mutation, leading to the R206H substitution in the GS domain of the ACVR1 receptor. In two patients, we found a novel mutation c.774G>C, leading to the R258S substitution in the kinase domain of the ACVR1 receptor. In the three-dimensional model of protein structure, R258 maps in close proximity to the GS domain, a key regulator of ACVR1 activity, where R206 is located. The GS domain is known to bind the regulatory protein FKBP12 and to undergo multiple phosphorylation events that trigger a signaling cascade inside the cell. The novel amino-acid substitution is predicted to influence either the conformation/stability of the GS region or the binding affinity with FKBP12, resulting in a less stringent inhibitory control on the ACVR1 kinase activity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18830232      PMCID: PMC2986177          DOI: 10.1038/ejhg.2008.178

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  30 in total

Review 1.  Controlling TGF-beta signaling.

Authors:  J Massagué; Y G Chen
Journal:  Genes Dev       Date:  2000-03-15       Impact factor: 11.361

2.  Prediction of deleterious human alleles.

Authors:  S Sunyaev; V Ramensky; I Koch; W Lathe; A S Kondrashov; P Bork
Journal:  Hum Mol Genet       Date:  2001-03-15       Impact factor: 6.150

3.  Accounting for human polymorphisms predicted to affect protein function.

Authors:  Pauline C Ng; Steven Henikoff
Journal:  Genome Res       Date:  2002-03       Impact factor: 9.043

4.  The TGF beta receptor activation process: an inhibitor- to substrate-binding switch.

Authors:  M Huse; T W Muir; L Xu; Y G Chen; J Kuriyan; J Massagué
Journal:  Mol Cell       Date:  2001-09       Impact factor: 17.970

5.  SWISS-MODEL: An automated protein homology-modeling server.

Authors:  Torsten Schwede; Jürgen Kopp; Nicolas Guex; Manuel C Peitsch
Journal:  Nucleic Acids Res       Date:  2003-07-01       Impact factor: 16.971

6.  SIFT: Predicting amino acid changes that affect protein function.

Authors:  Pauline C Ng; Steven Henikoff
Journal:  Nucleic Acids Res       Date:  2003-07-01       Impact factor: 16.971

Review 7.  Mechanisms of TGF-beta signaling from cell membrane to the nucleus.

Authors:  Yigong Shi; Joan Massagué
Journal:  Cell       Date:  2003-06-13       Impact factor: 41.582

8.  Early diagnosis of fibrodysplasia ossificans progressiva.

Authors:  Frederick S Kaplan; Meiqi Xu; David L Glaser; Felicity Collins; Michael Connor; Joseph Kitterman; David Sillence; Elaine Zackai; Vardit Ravitsky; Michael Zasloff; Arupa Ganguly; Eileen M Shore
Journal:  Pediatrics       Date:  2008-05       Impact factor: 7.124

9.  Human non-synonymous SNPs: server and survey.

Authors:  Vasily Ramensky; Peer Bork; Shamil Sunyaev
Journal:  Nucleic Acids Res       Date:  2002-09-01       Impact factor: 16.971

Review 10.  The immunophilin FKBP12: a molecular guardian of the TGF-beta family type I receptors.

Authors:  Tongwen Wang; Patricia K Donahoe
Journal:  Front Biosci       Date:  2004-01-01
View more
  43 in total

1.  ACVR1 p.Q207E causes classic fibrodysplasia ossificans progressiva and is functionally distinct from the engineered constitutively active ACVR1 p.Q207D variant.

Authors:  Julia Haupt; Alexandra Deichsel; Katja Stange; Cindy Ast; Renata Bocciardi; Roberto Ravazzolo; Maja Di Rocco; Paola Ferrari; Antonio Landi; Frederick S Kaplan; Eileen M Shore; Carsten Reissner; Petra Seemann
Journal:  Hum Mol Genet       Date:  2014-05-22       Impact factor: 6.150

2.  A novel ACVR1 mutation in the glycine/serine-rich domain found in the most benign case of a fibrodysplasia ossificans progressiva variant reported to date.

Authors:  Celia L Gregson; Peter Hollingworth; Martin Williams; Kirsten A Petrie; Alex N Bullock; Matthew A Brown; Jon H Tobias; James T Triffitt
Journal:  Bone       Date:  2010-10-29       Impact factor: 4.398

3.  Are great toes always abnormal in patients with fibrodysplasia ossificans progressiva?

Authors:  Sumeet Gulshan Dua; Nilendu C Purandare
Journal:  Eur J Pediatr       Date:  2011-02-02       Impact factor: 3.183

4.  Fibrodysplasia ossificans progressiva without characteristic skeletal anomalies.

Authors:  Hasan Ulusoy
Journal:  Rheumatol Int       Date:  2010-03-27       Impact factor: 2.631

Review 5.  Role of altered signal transduction in heterotopic ossification and fibrodysplasia ossificans progressiva.

Authors:  Eileen M Shore; Frederick S Kaplan
Journal:  Curr Osteoporos Rep       Date:  2011-06       Impact factor: 5.096

6.  The phenotype and genotype of fibrodysplasia ossificans progressiva in China: a report of 72 cases.

Authors:  Wei Zhang; Keqin Zhang; Lige Song; Jing Pang; Hongxing Ma; Eileen M Shore; Frederick S Kaplan; Peijun Wang
Journal:  Bone       Date:  2013-09-17       Impact factor: 4.398

7.  Shared ACVR1 mutations in FOP and DIPG: Opportunities and challenges in extending biological and clinical implications across rare diseases.

Authors:  Harry J Han; Payal Jain; Adam C Resnick
Journal:  Bone       Date:  2017-08-02       Impact factor: 4.398

Review 8.  Fibrodysplasia ossificans progressiva: clinical course, genetic mutations and genotype-phenotype correlation.

Authors:  Irina Hüning; Gabriele Gillessen-Kaesbach
Journal:  Mol Syndromol       Date:  2014-08-07

9.  A new form of IRIDA due to combined heterozygous mutations of TMPRSS6 and ACVR1A encoding the BMP receptor ALK2.

Authors:  Alessia Pagani; Silvia Colucci; Renata Bocciardi; Marta Bertamino; Carlo Dufour; Roberto Ravazzolo; Laura Silvestri; Clara Camaschella
Journal:  Blood       Date:  2017-05-05       Impact factor: 22.113

10.  Is there a biological basis for treatment of fibrodysplasia ossificans progressiva with rosiglitazone? Potential benefits and undesired effects.

Authors:  Renata Bocciardi; Roberto Ravazzolo
Journal:  PPAR Res       Date:  2010-06-16       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.